Jazz Pharma Inc v. Almaject Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:

  • Plaintiff: Jazz Pharmaceuticals, Inc. (Delaware) and Gentium S.r.l. (Italy)
  • Defendant: Almaject, Inc., Alvogen, Inc., and Alvogen PB Research and Development LLC (Delaware)
  • Plaintiff's Counsel: Saul Ewing LLP

• Case Identification: 2:26-cv-02629, D.N.J., 03/13/2026

• Venue Allegations: Plaintiff alleges venue is proper in the District of New Jersey because the defendant entities maintain regular and established places of business in the district and conduct substantial business there, including the marketing and sale of other generic pharmaceutical products.

• Core Dispute: Plaintiff alleges that Defendants' submission of an Abbreviated New Drug Application (ANDA) to the FDA for a generic version of Plaintiff's drug Defitelio® (defibrotide sodium) constitutes an act of patent infringement.

• Technical Context: The patents-in-suit relate to formulations of the drug defibrotide, defined by a specific biological potency as measured by a proprietary laboratory method, used for treating a rare and serious liver condition.

• Key Procedural History: The complaint notes that this case is related to a prior action in the same district involving the same parties and related patents. The complaint also states that the defendant entities have previously been sued in the District of New Jersey and have not challenged personal jurisdiction in those prior cases.

Case Timeline

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,529,052 - "Euglobulin-based Method for Determining the Biological Activity of Defibrotide" (Issued Jan. 20, 2026)

The Invention Explained

• Problem Addressed: Defibrotide is a substance of natural origin obtained by extraction from animal organs, and its composition is subject to batch-to-batch variability typical of natural biopolymers Compl., Ex. A, '052 Patent, col. 1:47-56 The patent notes that prior methods for evaluating the biological activity of defibrotide were either experimentally complex, lacked reproducibility, or did not accurately simulate the drug's mechanism of action in vivo '052 Patent, col. 2:16-22 '052 Patent, col. 2:45-51
• The Patented Solution: The patent describes an indirect enzymatic assay to reliably measure defibrotide's biological activity '052 Patent, abstract The method involves bringing a defibrotide sample into contact with a mammalian euglobulin fraction, which contains plasminogen '052 Patent, col. 3:25-28 Defibrotide catalyzes the conversion of plasminogen into plasmin; this plasmin then reacts with a specific substrate to produce a measurable product (e.g., a color change) '052 Patent, col. 3:38-43 The rate at which this product is formed is proportional to the biological activity of the defibrotide sample, allowing for standardization across different batches '052 Patent, col. 3:33-37
• Technical Importance: The described method provides a standardized, reproducible quality control tool for a biologically derived drug, aiming to ensure consistent potency and therapeutic effect for patients.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 '052 Patent, ¶37
• Claim 1 Elements:
  • A defibrotide formulation consisting of defibrotide, sodium citrate, a pH adjusting agent, and water for injection;
  • Having a potency of 25 to 35 IU/mg;
  • Having a concentration of at least 80 mg/mL;
  • Wherein the potency is determined by a method that includes (a) contacting defibrotide with a biological composition comprising plasminogen and a plasmin-specific substrate that provides a measurable product upon reaction, and (b) measuring the amount of product formed over time '052 Patent, col. 12:21-34
• The complaint does not explicitly reserve the right to assert dependent claims.

U.S. Patent No. 12,534,722 - "Euglobulin-based Method for Determining the Biological Activity of Defibrotide" (Issued Jan. 27, 2026)

The Invention Explained

• Problem Addressed: The '722 Patent addresses the same technical problem as the '052 Patent: the need for a reliable and reproducible method to measure and standardize the biological activity of defibrotide, a drug derived from natural sources with inherent batch-to-batch variability Compl., Ex. B, '722 Patent, col. 1:48-56
• The Patented Solution: The '722 Patent describes the same indirect enzymatic assay as the '052 Patent, based on defibrotide's ability to catalyze the conversion of plasminogen to plasmin in a euglobulin fraction, with the resulting activity measured via a plasmin-specific substrate '722 Patent, abstract '722 Patent, col. 3:28-43
• Technical Importance: As with the '052 Patent, this invention provides a method to ensure consistent quality and potency for a complex biological drug product.

Key Claims at a Glance

• The complaint asserts at least independent claim 1 '722 Patent, ¶47
• Claim 1 Elements:
  • A defibrotide formulation comprising defibrotide, sodium citrate, and water for injection;
  • Having a potency of 25 to 35 IU/mg;
  • Having a concentration of at least 80 mg/mL;
  • Wherein the potency is determined by a method that includes (a) contacting defibrotide with a biological composition comprising plasminogen and a plasmin-specific substrate that provides a measurable product upon reaction, and (b) measuring the amount of product formed over time '722 Patent, col. 12:11-24
• The complaint does not explicitly reserve the right to assert dependent claims.

III. The Accused Instrumentality

Product Identification

• Defendants' proposed generic drug product is described as "defibrotide sodium vials, 250 mg/2.5 mL" Compl. ¶32

Functionality and Market Context

• The complaint alleges that the proposed product is a generic version of Jazz's Defitelio® (defibrotide sodium) drug product Compl. ¶1 Defitelio® is an FDA-approved medication for treating hepatic veno-occlusive disease (VOD) in patients following hematopoietic stem-cell transplantation Compl. ¶10 Defendants submitted ANDA No. 216293 seeking FDA approval to manufacture and sell this generic version prior to the expiration of the patents-in-suit Compl. ¶1 Compl. ¶32 The formulation specified in the ANDA, 250 mg in 2.5 mL, corresponds to a concentration of 100 mg/mL Compl. ¶32

IV. Analysis of Infringement Allegations

The complaint alleges that the submission of ANDA No. 216293 constitutes a statutory act of infringement under 35 U.S.C. § 271(e)(2)(A) Compl. ¶37 Compl. ¶47 It alleges on information and belief that the product described in the ANDA will satisfy every element of at least claim 1 of both the '052 and '722 patents Compl. ¶38 Compl. ¶48 The complaint does not include a claim chart or provide specific factual allegations mapping elements of the claims to features of the accused product beyond what is required to state a claim in an ANDA litigation context.

No probative visual evidence provided in complaint.

• Identified Points of Contention:
  • Scope Questions: The asserted claims are for a formulation defined, in part, by a property ("potency") that is "determined by a method comprising" specific steps. A central legal question for claim construction may be whether this "product-by-process" language limits the claim to only those formulations that are actually tested using the recited euglobulin-based method, or whether it defines a characteristic of the formulation that could be infringed even if the defendant uses a different method for quality control.
  • Technical Questions: A key factual dispute will likely concern whether Defendants' proposed product will, upon approval, actually possess the claimed characteristics. This raises several questions: Does the proposed generic formulation have a potency within the claimed range of "25 to 35 IU/mg"? Does it meet the concentration of "at least 80 mg/mL"? (The alleged 250 mg/2.5 mL formulation would be 100 mg/mL, which meets this limitation). Evidence for these questions would reside within the confidential ANDA submission.

V. Key Claim Terms for Construction

• The Term: "wherein the defibrotide potency is determined by a method comprising the steps of..." '052 Patent, col. 12:25-26 '722 Patent, col. 12:15-16

• Context and Importance: The construction of this phrase will be critical. If interpreted as a strict process limitation, Plaintiff would have to show that Defendant's manufacturing or quality control process for its generic product involves the recited steps. If interpreted as merely defining a property of the end product, Plaintiff would only need to show that the generic product, if tested by the recited method, would yield a result in the claimed potency range.

  • Intrinsic Evidence for a Broader Interpretation: A party could argue that the patent's abstract, which states the invention is a "method for determining the biological activity," suggests the method is a measurement tool, not a manufacturing step '052 Patent, abstract This may support the view that the claim language defines a property of the formulation (i.e., its potency as measurable by the method), not how it was made or released.
  • Intrinsic Evidence for a Narrower Interpretation: A party could argue that the explicit recitation of method "steps" ("comprising the steps of: a) ... and b) ...") in the body of the claim is definitive language that limits the claim's scope to formulations where this specific method is used to ascertain potency '052 Patent, col. 12:27-34

• The Term: "a biological composition comprising plasminogen" '052 Patent, col. 12:28-29 '722 Patent, col. 12:18-19

• Context and Importance: The patent titles refer to a "Euglobulin-based Method," and the specification primarily describes using a euglobulin fraction. The scope of the broader term "biological composition comprising plasminogen" will be important in defining the boundaries of the method steps recited in the claim.

  • Intrinsic Evidence for a Broader Interpretation: The specification explicitly contemplates other systems, stating that "the use of other equivalent enzymatic systems, such as, for example, diluted plasma and serum ... falls within the scope of the present invention" '052 Patent, col. 4:18-24 This language may support a construction not limited to the euglobulin embodiment.
  • Intrinsic Evidence for a Narrower Interpretation: A party could argue that the consistent focus on euglobulin as the "enzymatic system of choice" and the "preferred" embodiment throughout the specification should limit the claim term to euglobulin or its direct equivalents, despite the broader claim language '052 Patent, col. 4:15-16

VI. Other Allegations

• Indirect Infringement: The complaint alleges that upon FDA approval, Defendants will induce and contribute to infringement of the patents-in-suit Compl. ¶41 Compl. ¶42 The basis for inducement is the allegation that Defendants will "intentionally encourage acts of direct infringement" with knowledge of the patents Compl. ¶41 Compl. ¶51 The basis for contributory infringement is the allegation that the proposed product is "especially adapted for a use that infringes" and has "no substantial non-infringing use" Compl. ¶42 Compl. ¶52
• Willful Infringement: The complaint does not contain an explicit allegation of willful infringement. However, it does allege that the case is "exceptional" and seeks an award of attorneys' fees pursuant to 35 U.S.C. § 285 Compl. ¶45 Compl. ¶55 The alleged basis for Defendants' knowledge of the patents is the Paragraph IV Certification letter sent to Jazz no earlier than March 4, 2026 Compl. ¶35

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: will the "product-by-process" language in the asserted claims be construed as a strict process limitation, requiring Plaintiff to prove that Defendants use the recited euglobulin-based test, or will it be construed as defining an inherent property of the formulation, allowing infringement to be proven by showing the generic product simply possesses the claimed potency?
• A key evidentiary question will be one of technical compliance: does the formulation described in Defendants' confidential ANDA filing, in fact, have a potency of 25 to 35 IU/mg and a defibrotide concentration of at least 80 mg/mL, thus falling within the scope of the asserted claims, regardless of how claim scope is ultimately defined?